REVIEW PAPER
Morphea – selected local treatment methods and their effectiveness
Submission date: 2017-11-22
Final revision date: 2017-11-29
Acceptance date: 2017-11-30
Online publication date: 2017-12-30
Publication date: 2017-12-31
Reumatologia 2017;55(6):305-313
KEYWORDS
TOPICS
ABSTRACT
Localised scleroderma is an uncommon connective tissue disease of multifactorial aetiology occurring in the paediatric and adult population. It is relatively difficult to conduct any research on the subject of this disease entity treatment due to the low number of patients suffering from morphea, a tendency of the disease to remit spontaneously, and not yet well recognised aetiology. Hence, there has been developed no causal treatment of well-proven effectiveness, and schedules of symptomatic therapy are not yet clearly determined. The paper depicts most widely used topical treatment methods in morphea therapy, which due to minor risk of systemic adverse effects seem to be a beneficial therapeutic alternative. The main aim of this article was to analyse different topical treatment options used in localised scleroderma therapy and to indicate the most appropriate, safe, and effective one.
REFERENCES (61)
1.
Sartori-Valinotti JC, Tollefson MM, Reed AM. Updates on morphea: role of vascular injury and advances in treatment. Autoimmune Dis 2013; 2013: 467808.
2.
Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64: 217-228.
4.
Cox LA, Webster GF, Piera-Velazquez S, et al. Multiplex assessment of serum cytokine and chemokine levels in idiopathic morphea and vitamin K1-induced morphea. Clin Rheumatol 2017; 36: 1173-1178.
5.
Torok KS, Kurzinski K, Kelsey C, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum 2015; 45: 284-293.
6.
Saracino AM, Denton CP, Orteu CH. The molecular pathogenesis of morphoea: from genetics to future treatment targets. Br J Dermatol 2017; 177: 34-46.
7.
Valančienė G, Jasaitienė D, Valiukevičienė S. Pathogenesis and treatment modalities of localized scleroderma. Medicina (Kaunas) 2010; 46: 649-656.
8.
Mertens JS, Seyger MMB, Thurlings RM, et al. Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol 2017; 18: 491-512.
9.
Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol 2007; 157: 615-618.
10.
Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol 2015; 90: 62-73.
11.
Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 2016; 14: 199-216.
12.
Distler O, Cozzio A. Systemic sclerosis and localized scleroderma-current concepts and novel targets for therapy. Semin Immunopathol 2016; 38: 87-95.
13.
Chi CC, Wang SH, Mayon-White R, et al. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol 2013; 149: 1274-1280.
14.
Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corticosteroids in pregnancy: a population-based cohort study. J Invest Dermatol 2011; 131: 884-891.
15.
Kroft EB, Groneveld TJ, Seyger MM, et al. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009; 10: 181-187.
16.
Stefanaki C, Stefanaki K, Kontochristopoulos G, et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 2008; 35: 712-718.
17.
Cantisani C, Miraglia E, Richetta AG, et al. Generalized morphea successfully treated with tacrolimus 0.1% ointment.
19.
Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005; 152: 180-182.
20.
Bhari N, Saginatham H, Verma KK. Tacrolimus induced dermatophyte infection overlying a plaque morphea. Dermatol Ther 2017; 30. doi: 10.1111/dth.12395.
21.
Chu CH, Cheng YP, Liang CW, et al. Radiation recall dermatitis induced by topical tacrolimus for post-irradiation morphea. J Eur Acad Dermatol Venereol 2017; 31: e80-e81.
22.
Cunningham BB, Landells ID, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998; 39: 211-215.
23.
Ascari-Raccagni A, Dondas A, Dubini A, et al. Biopsy proven morphea treated with tacalcitol ointment: case report. Acta Dermatovenerol Croat 2010; 18: 248-251.
24.
Santos G, Sousa L, Joao A, et al. Linear morphea – a case treated with calcipotriol and betamethasone dipropionate. Eur.
26.
Kreuter A, Gambichler T, Avermaete A. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001; 18: 241-245.
27.
Gambichler T, Kreuter A, Rotterdam S, et al. Linear scleroderma ‘en coup de sabre’ treated with topical calcipotriol and cream psoralen plus ultraviolet A. J Eur Acad Dermatol Venereol 2003; 17: 601-602.
28.
Diaz A, Jiménez SA. Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms. Int J Biochem Cell Biol 1997; 29: 251-260.
29.
Campione E, Paterno EJ, Diluvio L, et al. Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness. J Dermatolog Treat 2009; 20: 10-13.
30.
Dytoc M, Ting PT, Man J, et al. First case series on the use of imiquimod for morphea. Br J Dermatol 2005; 153: 815-820.
31.
Dytoc M, Wat H, Cheung-Lee M, et al. Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial. J Cutan Med Surg 2015; 19: 132-139.
32.
Pope E, Doria AS, Theriault M, et al. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology 2011; 223: 363-369.
33.
Hunzelmann N, Anders S, Fierlbeck G, et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997; 36: 433-435.
34.
Teske NM, Jacobe HT. Phototherapy for sclerosing skin conditions. Clin Dermatol 2016; 34: 614-622.
35.
Kreuter A, Gambichler T. UV-A1 phototherapy for sclerotic skin diseases: implications for optimizing patient selection and management. Arch Dermatol 2008; 144: 912-916.
36.
Gruss C, Reed JA, Altmeyer P, et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350: 1295-1296.
37.
Kreuter A, Hyun J, Skrygan M, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 2006; 155: 600-607.
38.
El-Mofty M, Mostafa W, Esmat S, et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed 2004; 20: 93-100.
39.
Nisar MF, Parsons KS, Bian CX, et al. UVA irradiation induced heme oxygenase-1: a novel phototherapy for morphea. Photochem Photobiol 2015; 91: 210-220.
40.
Hassani J, Feldman SR. Phototherapy in Scleroderma. Dermatol Ther (Heidelb) 2016; 6: 519-553.
41.
Su O, Onsun N, Onay HK, et al. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma. Int J Dermatol 2011; 50: 1006-1013.
42.
Tuchinda C, Kerr HA, Taylor CR, et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 2006; 22: 247-253.
43.
Jacobe HT, Cayce R, Nguyen J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I–V. Br J Dermatol 2008; 159: 691-696.
44.
Wang F, Garza LA, Cho S, et al. Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy. Arch Dermatol 2008; 144: 851-858.
45.
de Rie MA, Enomoto DN, de Vries HJ, et al. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 2003; 207: 298–301.
46.
Andres C, Kollmar A, Mempel M, et al. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2010; 162: 445-447.
47.
Gruss CJ, Von Kobyletzki G, Behrens-Williams SC, et al. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001; 17: 149-155.
48.
Kreuter A, Hyun J, Stücker M, et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54: 440-447.
49.
Vasquez R, Jabbar A, Khan F, et al. Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study. J Am Acad Dermatol 2014; 70: 481-488.
50.
Bulat V, Situm M, Dediol I, et al. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol 2011; 35 Suppl 2: 147-151.
51.
Uchiyama M, Okubo Y, Kawashima H, et al. Case of localized scleroderma successfully treated with bath psoralen and ultraviolet A therapy. J Dermatol 2010; 37: 75-80.
52.
Morison W. Psoralen UVA therapy for linear and generalized morphea. J Am Acad Dermatol 1997; 37: 657-659.
53.
Baskan EB, Kacar SD, Turan A, et al. Parry-Romberg syndrome associated with borreliosis: could photochemotherapy halt the progression of the disease? Photodermatol Photoimmunol Photomed 2006; 22: 259-261.
54.
Buense R, Duarte IA, Bouer M. Localized scleroderma: assessment of the therapeutic response to phototherapy. An Bras Dermatol 2012; 87: 63-69.
55.
Grundmann-Kollmann M, Ochsendorf F, Zollner TM, et al. PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000; 43: 675-678.
56.
Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252-258.
57.
Kim YS, Park YL, Lee JS, et al. Multiple actinic keratosis, squamous cell carcinoma and basal cell carcinoma occurred after PUVA therapy in a Korean patient. Photodermatol Photoimmunol Photomed 2014; 30: 277-279.
58.
Babilas P, Schreml S, Landthaler M, et al. Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed 2010; 26: 118-132.
59.
Karrer S, Bosserhoff AK, Weiderer P, et al. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br J Dermatol 2004; 151: 776-783.
60.
Karrer S, Abels C, Landthaler M, et al. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 2000; 80: 26-27.
61.
Batchelor R, Lamb S, Goulden V, et al. Photodynamic therapy for the treatment of morphoea. Clin Exp Dermatol 2008; 33: 661-663.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
